Akebia Therapeutics (AKBA) News Today $2.42 -0.04 (-1.43%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Akebia Therapeutics (NASDAQ:AKBA) Upgraded to Hold at StockNews.comStockNews.com upgraded Akebia Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday.May 5 at 2:35 AM | marketbeat.comQ1 Earnings Estimate for AKBA Issued By Leerink PartnrsAkebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Akebia Therapeutics in a research note issued on Monday, April 28th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical companyMay 3 at 7:12 AM | marketbeat.comAkebia Therapeutics (AKBA) to Release Quarterly Earnings on ThursdayAkebia Therapeutics (NASDAQ:AKBA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-akebia-therapeutics-inc-stock/)May 3 at 3:50 AM | marketbeat.comWhat is Leerink Partnrs' Estimate for AKBA Q1 Earnings?May 3 at 2:01 AM | americanbankingnews.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Receives $6.63 Consensus Target Price from AnalystsMay 3 at 1:07 AM | americanbankingnews.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of "Buy" by AnalystsAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) has been assigned an average rating of "Buy" from the five analysts that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buyMay 2 at 8:20 AM | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Upgraded to "Strong-Buy" at Leerink PartnrsLeerink Partnrs raised shares of Akebia Therapeutics to a "strong-buy" rating in a report on Monday.May 2 at 7:50 AM | marketbeat.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comAkebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business HighlightsMay 1, 2025 | finance.yahoo.comAkebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business HighlightsMay 1, 2025 | globenewswire.comAkebia Therapeutics (AKBA) Expected to Announce Earnings on ThursdayMay 1, 2025 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Shares Gap Up - Should You Buy?Akebia Therapeutics (NASDAQ:AKBA) Shares Gap Up - Here's What HappenedApril 30, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Coverage Initiated by Analysts at Leerink PartnersLeerink Partners began coverage on shares of Akebia Therapeutics in a report on Monday. They issued an "outperform" rating and a $7.00 price target on the stock.April 30, 2025 | marketbeat.comLeerink Partners Initiates Coverage of Akebia Therapeutics (AKBA) with Outperform RecommendationApril 30, 2025 | msn.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Bought by JPMorgan Chase & Co.JPMorgan Chase & Co. raised its position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 363.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 456,294 shares of the biopharmaceuticalApril 30, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Now Covered by Leerink PartnersApril 29, 2025 | americanbankingnews.comVanguard Group Inc. Grows Stock Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA)Vanguard Group Inc. raised its stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 8.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,884,200 shares of the biopharmaceutical company's sApril 17, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at StockNews.comStockNews.com upgraded shares of Akebia Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.April 12, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA)HC Wainwright reissued a "buy" rating and issued a $7.50 price target on shares of Akebia Therapeutics in a report on Friday.April 6, 2025 | marketbeat.comAkebia Therapeutics: CHMP Adopts Positive Opinion On XOANACYL - Quick FactsApril 5, 2025 | nasdaq.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.comStockNews.com downgraded shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.April 4, 2025 | marketbeat.comAkebia announces CHMP positive opinion for XOANACYLApril 4, 2025 | markets.businessinsider.comAkebia Therapeutics gets EU positive recommendation for XoanacylApril 3, 2025 | msn.comAkebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to AveroaApril 3, 2025 | globenewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | globenewswire.comAkebia Therapeutics (NASDAQ:AKBA) Coverage Initiated by Analysts at Jefferies Financial GroupJefferies Financial Group began coverage on shares of Akebia Therapeutics in a report on Tuesday. They set a "buy" rating and a $6.00 price objective on the stock.April 2, 2025 | marketbeat.comAkebia initiated with a Buy at JefferiesApril 2, 2025 | markets.businessinsider.comJefferies Initiates Coverage of Akebia Therapeutics (AKBA) with Buy RecommendationApril 2, 2025 | msn.comAnalysts Love These 2 Growth Stocks That Have Over 200% Upside PotentialApril 1, 2025 | msn.comAkebia Therapeutics to Present Research at National Kidney Foundation Spring Clinical Meetings 2025March 27, 2025 | nasdaq.comAkebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025March 25, 2025 | globenewswire.comAkebia Therapeutics, Inc. Announces Underwritten Public Offering of Common StockMarch 21, 2025 | nasdaq.comAkebia's Valuation Looks Stretched Despite Auryxia's Loss Of ExclusivityMarch 21, 2025 | seekingalpha.comWhy Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?March 21, 2025 | msn.comAkebia 25M share Spot Secondary priced at $2.00March 20, 2025 | markets.businessinsider.comAkebia Therapeutics (NASDAQ:AKBA) Shares Up 11.2% - Here's What HappenedAkebia Therapeutics (NASDAQ:AKBA) Shares Up 11.2% - Should You Buy?March 20, 2025 | marketbeat.comAkebia announces common stock offering, no amount givenMarch 20, 2025 | markets.businessinsider.comJOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionMarch 20, 2025 | benzinga.comAkebia Therapeutics Announces Pricing of Public Offering of Common StockMarch 19, 2025 | globenewswire.comIs Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game?March 19, 2025 | insidermonkey.comAkebia Therapeutics Announces Proposed Public Offering of Common StockMarch 19, 2025 | globenewswire.comAkebia Therapeutics (NASDAQ:AKBA) Hits New 52-Week High - What's Next?Akebia Therapeutics (NASDAQ:AKBA) Hits New 52-Week High - Still a Buy?March 19, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Upgraded at StockNews.comStockNews.com upgraded Akebia Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday.March 18, 2025 | marketbeat.comUS$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These ResultsMarch 16, 2025 | finance.yahoo.comAkebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | seekingalpha.comAkebia Therapeutics Target of Unusually Large Options Trading (NASDAQ:AKBA)Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the recipient of some unusual options trading on Friday. Investors bought 3,386 call options on the stock. This represents an increase of 303% compared to the typical daily volume of 841 call options.March 15, 2025 | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for Akebia Therapeutics (NASDAQ:AKBA) StockPiper Sandler raised their target price on Akebia Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday.March 15, 2025 | marketbeat.comAkebia Therapeutics' (AKBA) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.50 target price on shares of Akebia Therapeutics in a research note on Friday.March 15, 2025 | marketbeat.comAkebia price target raised to $6 from $4 at Piper SandlerMarch 14, 2025 | markets.businessinsider.comAkebia Therapeutics (NASDAQ:AKBA) Posts Earnings Results, Misses Expectations By $0.05 EPSAkebia Therapeutics (NASDAQ:AKBA - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05).March 14, 2025 | marketbeat.com Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Media Mentions By Week AKBA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKBA News Sentiment▼0.730.73▲Average Medical News Sentiment AKBA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKBA Articles This Week▼213▲AKBA Articles Average Week Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies APLS News IBRX News BHVN News AAPG News KYMR News CGON News MTSR News MIRM News BHC News BEAM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKBA) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKBA Stock Free AKBA Stock Alerts